Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

AUGUST 24, 2021

Patent protects methods of administering MYMD-1 for treating disorders associated with chronic inflammation, with a focus on fibrosis and asthma. BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. Investor Contact: Robert Schatz.

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. About Supera-CBD.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

OCTOBER 5, 2021

MyMD to launch two simultaneous Phase 2 trials during the current quarter to study MYMD-1’s function in extending healthy lifespan and treating COVID-19-associated depression. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Media 52

Cannabis Law Report

NOVEMBER 18, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax is also preparing to commence clinical trials in Israel.”.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 22, 2021

New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. We believe that the new data we are revealing today is an extraordinary achievement in the field of pharmaceutical cannabinoids,” said Adam Kaplin, M.D.,

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

DECEMBER 28, 2021

–(BUSINESS WIRE)– #pharma –Virpax ® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX) achieved significant milestones relating to its pipeline of product candidates as of the end of 2021, which are summarized below. “I About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

OCTOBER 26, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that Chris Chapman, M.D., Chapman has operated Chapman Pharmaceutical Consulting, Inc., MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

DECEMBER 29, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax is also preparing to commence clinical trials in Israel.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

NOVEMBER 16, 2021

Phase 2 trial recruiting begins immediately; efficacy data expected by the end of the first quarter of 2022. BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. tumor necrosis factor receptor I (TNFRI) and IL-6. MyMD Contact: Robert Schatz.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

NOVEMBER 15, 2021

–(BUSINESS WIRE)– #earnings — Virpax ® Pharmaceuticals, Inc. We continue to enhance our product pipeline, and because of our unique delivery technologies we have expanded our targeted indications beyond pain to include Central Nervous System (CNS) disorders and anti-viral indications. “Our

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 2 Goates et al.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Cannabis Law Report

DECEMBER 8, 2021

.–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. This data should strengthen the Company’s IND filing in advance of the anticipated start of first-in-human clinical trials. About Virpax Pharmaceuticals. Mack, Chairman and CEO of Virpax. For more information, please visit www.virpaxpharma.com.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” ” . . In addition, Gb Sciences has 12 U.S. 31, 2021.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52

Cannabis Law Report

AUGUST 2, 2021

Study Results Indicate SCI-160 Has A Significant Analgesic Effect on Acute and Chronic Pain. Key findings from the pre-clinical trial are as follows: SCI-160 significantly alleviates pain up to 6 hours after injection as compared with vehicle-treated animals. TEL AVIV, Israel , Aug. Logo – [link].

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Project CBD

MAY 3, 2023

She is the medical director of Canna-Centers Wellness & Education and the clinical advisor to Cannformatics. She is also the author of Cannabis is Medicine: How Medical Cannabis and CBD are Healing Everything from Anxiety to Chronic Pain. Remember, the pharmaceutical model is “this medicine addresses this specific target.”

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

OCTOBER 6, 2021

With the additional funding recently secured by Virpax and the strengthening of our balance sheet, we are continuing to advance our product candidates and to move them through preclinical studies and into human clinical trials,” said Anthony Mack, Chairman and Chief Executive Officer of Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Research and Development 52

Research and Development Clinical Trials Pharmaceutical Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. The NIH has also engaged a firm to manufacture Leu-enkephalin (L-ENK), the active ingredient in Envelta and a firm to manufacture the Molecular Envelope Technology (MET) that is used to carry the L-ENK to the brain to promptly suppress pain.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Veriheal

JULY 12, 2021

According to the American Psychiatric Association , PTSD is a “psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as natural disaster, as a serious accident, a terrorist act, war/combat or rape or who have been threatened with death, sexual violence or serious injury”.

Treatment 104

Treatment Sleep Clinical Trials Data 104

Cannabis Law Report

OCTOBER 1, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that Chairman and CEO Anthony P. About Virpax Pharmaceuticals. BERWYN, Pa.–(BUSINESS

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

Cannabis Law Report

SEPTEMBER 20, 2021

–(BUSINESS WIRE)– #pharma — Virpax ® Pharmaceuticals, Inc. Virpax” or the “Company”) (NASDAQ:VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, has acquired the exclusive worldwide rights from Nanomerics Ltd. About Virpax Pharmaceuticals.

Epilepsy 52

Epilepsy Research and Development Clinical Trials Chronic Pain 52

Puff Puff Post

SEPTEMBER 16, 2019

Event details below: Date: Tuesday, September 17th 2019. The clinical care team is comprised of family physicians and specialists in chronic pain , cancer, gastroenterology, and endocrinology, as well as nurses with clinical expertise in cannabis medicine. Time: 9:00AM to 5:00PM. ABOUT SPECTRUM THERAPEUTICS.

Programs 108

Programs Research and Development Education Treatment 108

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Knowing these can allow you or your healthcare provider to look up the metabolism of a pharmaceutical drug and determine if a CBD-drug interaction is possible.

CBD 98

CBD THC Conditions Medicine 98

Puff Puff Post

SEPTEMBER 16, 2019

Event details below: Date: Tuesday, September 17th 2019. The clinical care team is comprised of family physicians and specialists in chronic pain , cancer, gastroenterology, and endocrinology, as well as nurses with clinical expertise in cannabis medicine. Time: 9:00AM to 5:00PM. ABOUT SPECTRUM THERAPEUTICS.

Programs 40

Programs Research and Development Education Treatment 40

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions.[1]. Knowing these can allow you or your healthcare provider to look up the metabolism of a pharmaceutical drug and determine if a CBD-drug interaction is possible.

CBD 52

CBD THC Conditions Medicine 52

Green Relief

MAY 13, 2018

As yet there have been no FDA -approved clinical trials to determine the efficacy of CBD -rich cannabis oil extracts for traumatic brain injury. Treatment modalities for TBI are limited with few satisfactory pharmaceutical options available. And in many places, cannabis is still not available as a legal therapeutic option.

THC 64

THC CBD Cannabinoids Research and Development 64

Cannabis Law Report

NOVEMBER 24, 2021

Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Pain and chronic pain were the most common conditions mentioned over the time period and were referred to in 62% of all articles.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 30, 2019

State lawmakers passed Assembly Bill 420 , which authorizes the University of California’s Center for Medicinal Cannabis Research to cultivate cannabis for clinical trials. Specifically, it expands the pool of patients eligible for cannabis therapy to include those with chronic pain, menstrual cramps, and epilepsy.

Legislation 59

Legislation Patients Access Banking 59

Cannabis Law Report

OCTOBER 17, 2019

Some of the potential health benefits associated with THC and CBD, with and without the high, respectively, include reducing chronic pain such as from migraines or cancer, alleviating anxiety, reducing inflammation, and helping treat conditions such as epilepsy, PTSD, and glaucoma.

Law 40

Law Seed-To-Sale Hemp Recreational 40